A coronavirus vaccine developed by Britain’s University of Oxford and the pharmaceutical firm AstraZeneca has shown successful results in early trials. If it is approved by regulators, the vaccine appears suitable for a fast rollout around the globe. Early analysis of trials involving 20,000 volunteers in Britain and Brazil show the vaccine is at least 62% effective after two doses. In volunteers given a different dosing regimen — a half dose, followed by a full dose — that figure rose to 90%. The average efficacy of the two dosing methods is 70%. None of those given the vaccine developed severe COVID-19 illness. Andrew Pollard, director of the Oxford Vaccine Group, said the recent successful trials of three different vaccines by Oxford-AstraZeneca, Pfizer-BioNTech and Moderna, represent a...
Egypt to probe four coronavirus deaths due to alleged lack of oxygen
Egyptian prosecutors opened an investigation into the deaths on Sunday of at least four coronavirus patients at a public Egyptian hospital, after a video of nurses struggling to keep the patients alive was shared widely on social media. The governor of Sharqia province denied allegations by a relative of one of the patients that the deaths were caused by a lack of oxygen at the government-run intensive care unit treating COVID-19 patients. Governor Mamdouh Ghorab said the patients died because they suffered chronic diseases in addition to the virus. The relative, who also filmed the video, offered no immediate evidence to back up their claim that the hospital ran out of oxygen. Egypt, the Arab world’s most populous country with more than 100 million people, is facing a surge in confirmed v...